3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
25
Squamous Cell Carcinoma of Head and Neck
10
Lung Neoplasms
10
Neoplasms
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Esophageal Squamous Cell Carcinoma
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Carcinoma, Squamous Cell
4
Stomach Neoplasms
3
Esophageal Neoplasms
3
Brain Neoplasms
3
Prostatic Neoplasms
2
Non-small-cell Lung Cancer With Somatic EGFR Mutations
2
NSCLC
2
Glioblastoma
2
Colorectal Neoplasms
2
Adenocarcinoma of Lung
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unilateral HER2 Positive Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Squamous Cell Cancers of the Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Interventions
Etoposide
79
Carboplatin
67
Cisplatin
58
durvalumab
29
Irinotecan
29
Radiotherapy
27
atezolizumab
23
Topotecan
21
anlotinib
19
Nivolumab
15
Drug Therapy
15
Radiosurgery
14
Gemcitabine
13
apatinib
12
Paclitaxel
12
toripalimab
10
Platinum
10
Docetaxel
10
tislelizumab
9
Temozolomide
9
PM 01183
8
pembrolizumab
7
olaparib
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Bevacizumab
7
Albumin-Bound Paclitaxel
7
irinotecan sucrosofate
6
Counseling
6
sintilimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Small Cell Lung Carcinoma
×
Afatinib
×
Clear all
NCT02876081
2017-09-11
THEN
Fondation Hôpital Saint-Joseph
Phase 2
Withdrawn